Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Pass Above 200-Day Moving Average – Here’s What Happened

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.80 and traded as high as $4.24. Cumberland Pharmaceuticals shares last traded at $4.15, with a volume of 28,715 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 6th.

Cumberland Pharmaceuticals Stock Performance

The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $56.71 million, a price-to-earnings ratio of -5.27 and a beta of -0.24. The stock’s 50 day moving average price is $4.90 and its two-hundred day moving average price is $2.84.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter. The firm had revenue of $10.44 million during the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP grew its holdings in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 94.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,649 shares of the specialty pharmaceutical company’s stock after purchasing an additional 18,271 shares during the quarter. Two Sigma Investments LP owned approximately 0.27% of Cumberland Pharmaceuticals worth $89,000 at the end of the most recent quarter. Institutional investors and hedge funds own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.